Mirum Pharmaceuticals, Inc.
MIRM
Clasificación en acciones
#3271
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Precio por acción
$82.73
Capitalización bursátil
$5.37B
Cambio (1 día)
0.60%
Cambio (1 año)
13.28%
País
US
Comercio Mirum Pharmaceuticals, Inc. (MIRM)
Categoría
Healthcare
Ganancias de Mirum Pharmaceuticals, Inc. (MIRM)
Ganancias en Jun 2026 TTM: $-857.54M
Secondo gli ultimi rapporti finanziari di Mirum Pharmaceuticals, Inc., gli utili attuali della società sono $-857.54M. Nel 2023, la società ha registrato un utile di $-162.42M, una disminución en comparación con agli utili del 2022, che erano di $-142.07M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Mirum Pharmaceuticals, Inc. desde 2018 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-857.54M | 886.67% |
| 2024 | $-86.91M | -46.49% |
| 2023 | $-162.42M | 14.33% |
| 2022 | $-142.07M | 69.23% |
| 2021 | $-83.95M | -18.70% |
| 2020 | $-103.26M | 96.57% |
| 2019 | $-52.53M | 202.81% |
| 2018 | $-17.35M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -715.12% |
US
|
|
| $-3.09B | 259.98% |
US
|
|
| $-4.02B | 368.34% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -327.47% |
NL
|
